These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31029618)

  • 1. Influence of Tyrosine Kinase Inhibitor, Nilotinib, on Delayed Healing of Bare-Metal Stents in Superficial Femoral Arteries: Insights From Angioscopic Findings.
    Kuwasaki S; Koga S; Akashi R; Ikeda S; Kawano H; Maemura K
    JACC Cardiovasc Interv; 2019 May; 12(10):e85-e86. PubMed ID: 31029618
    [No Abstract]   [Full Text] [Related]  

  • 2. Vascular response to paclitaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angioscopic findings from the SHIMEJI trial (Suppression of vascular wall Healing after IMplantation of drug Eluting peripheral stent in Japanese patients with the Infra inguinal lesion: serial angioscopic observation).
    Tsukiyama Y; Shinke T; Ishihara T; Otake H; Terashita D; Kozuki A; Fukunaga M; Zen K; Horimatsu T; Fujii K; Shite J; Uematsu M; Takahara M; Iida O; Nanto S; Hirata KI
    Int J Cardiovasc Imaging; 2019 Oct; 35(10):1777-1784. PubMed ID: 31201589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angioscopic Findings on 15-Month Follow-Up for Interwoven Nitinol Stent Invagination in the Femoropopliteal Artery.
    Nakama T; Obunai K; Muraishi M; Kojima S; Watanabe H
    JACC Cardiovasc Interv; 2020 Aug; 13(16):1958-1959. PubMed ID: 32739298
    [No Abstract]   [Full Text] [Related]  

  • 4. Very Late Histopathologic Evaluation of Neointimal Characteristics after Bare-Metal Stent Implantation in the Superficial Femoral Artery.
    Shiraki T; Iida O; Inoue K; Goto T; Mano T; Sakata Y
    J Vasc Interv Radiol; 2019 Apr; 30(4):616-617. PubMed ID: 30910186
    [No Abstract]   [Full Text] [Related]  

  • 5. [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].
    Gautier V; Mirault T; Azarine A; Alsac JM; Sapoval M; Réa D; Messas E
    J Mal Vasc; 2015 Jul; 40(4):231-9. PubMed ID: 26139550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
    Mirault T; Rea D; Azarine A; Messas E
    Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Anomalous Mechanism Causing Failure of Expanded Polytetrafluoroethylene-Covered Nitinol Stents, Evaluated Using Multiple Intravascular Imaging Modalities.
    Kobayashi N; Takano M; Miyauchi Y; Shimizu W
    JACC Cardiovasc Interv; 2020 Apr; 13(8):e73-e75. PubMed ID: 32222441
    [No Abstract]   [Full Text] [Related]  

  • 8. High-Resolution Angioscopy of Endoluminal Stent Graft at 6 Months After Implantation.
    Hoyano M; Ozaki K; Nishida K; Sakai R; Kubota N; Takano T; Okubo T; Kimura S; Yanagawa T; Ozawa T; Kashimura T; Minamino T
    Circ J; 2019 Aug; 83(9):1970. PubMed ID: 30842362
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis.
    Gongora CA; Shibuya M; Wessler JD; McGregor J; Tellez A; Cheng Y; Conditt GB; Kaluza GL; Granada JF
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1115-1123. PubMed ID: 26117470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Fluoropolymer-Based Paclitaxel Delivery on Neointimal Proliferation and Vascular Healing: A Comparative Peripheral Drug-Eluting Stent Study in the Familial Hypercholesterolemic Swine Model of Femoral Restenosis.
    Gasior P; Cheng Y; Valencia AF; McGregor J; Conditt GB; Kaluza GL; Granada JF
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28487355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathology and Multimodality Imaging of Acute and Chronic Femoral Stenting in Humans.
    Kuntz SH; Torii S; Jinnouchi H; Cornelissen A; Sakamoto A; Sato Y; Kutyna M; Romero ME; Lejay A; Schwein A; Bonnin E; Finn AV; Chakfé N; Virmani R
    JACC Cardiovasc Interv; 2020 Feb; 13(4):418-427. PubMed ID: 32081234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strut Coverage After Paclitaxel-Eluting Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Fukunaga M; Nishimura M; Horimatsu T; Saita T; Sumiyoshi A; Tamaru H; Imanaka T; Shibuya M; Naito Y; Masuyama T; Ishihara M
    JACC Cardiovasc Imaging; 2016 Jun; 9(6):753-5. PubMed ID: 26298069
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 14. Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia.
    Tokatlı M; Ismayilov R; Erkin Çınar O; Haznedaroğlu İC
    Turk J Haematol; 2024 Mar; 41(1):59-60. PubMed ID: 38153228
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.
    Lai GM; Yan SL; Chang CS; Tsai CY
    World J Gastroenterol; 2013 Feb; 19(8):1318-21. PubMed ID: 23483799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple squamous cell carcinomas following introduction of nilotinib.
    Peters P; Rabbolini D; Sinnya S; Khosrotehrani K; Wagner G
    Clin Exp Dermatol; 2014 Oct; 39(7):791-4. PubMed ID: 25155911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
    Tefferi A
    Leukemia; 2013 Sep; 27(9):1939-40. PubMed ID: 23604230
    [No Abstract]   [Full Text] [Related]  

  • 18. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
    Khouri S; Kotliroff A; Lishner M; Amital H
    Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
    [No Abstract]   [Full Text] [Related]  

  • 19. The association of statin therapy with the primary patency of femoral and popliteal artery stents.
    de Grijs D; Teixeira P; Katz S
    J Vasc Surg; 2018 May; 67(5):1472-1479. PubMed ID: 29224939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
    Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
    Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.